Immuno-oncology
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
News
Patient-reported outcomes support first-line pembrolizumab for NSCLC
At week 18 in KEYNOTE-407, more patients in the pembrolizumab plus chemotherapy group reported improvements in health-related quality of life,...
News
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer
More than four in five patients were alive and free of disease progression a year after receiving chemoradiotherapy followed by ipilimumab, and...
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
News
Atezolizumab/bevacizumab may offer benefit to patients with RCC
The combination performed better in renal cell carcinoma patients who were PD-L1 positive.
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
Conference Coverage
Combo produces disappointing PFS, promising OS in metastatic colorectal cancer
NATIONAL HARBOR, MD. – Combination avelumab and cetuximab plus oxaliplatin, leucovorin, and 5-fluorouracil failed to meet the primary endpoint for...